Drugs / ATHENA CAR-T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06373991 | Jul 2024 → Apr 2027 expected | systemic lupus erythematosus | EdiGene Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT06014073 | Sep 2023 → Sep 2025 overdue | non-Hodgkin lymphoma | Chinese PLA General Hospital | Recruiting | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATHENA CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06014073 ↗ |
| Modality | Cell therapy | “ATHENA CAR-T injection” NCT06373991 ↗ |
| Target | CD19 | “TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T” NCT06014073 ↗ |